Merck (MRK) Receives FDA Approval for GARDASIL(R) in Boys and Young Men
Down)
Merck & Co., Inc. (NYSE: MRK) announced today that the U.S. FDA has approved GARDASIL(R) [Human Papillomavirus Quadrivalent (Types 6, 11, 16, and 18) Vaccine, Recombinant] for use in boys and men 9 through 26 years of age for the prevention of genital warts caused by human papillomavirus types 6 and 11. FDA approval is the first step in an important two-step process. The next step in the process is an Advisory Committee on Immunization Practices vote on whether to recommend administration of GARDASIL for use in males, as well as public funding through the U.S. Centers for Disease Control and Prevention contract. These votes are expected on October 21.
You May Also Be Interested In
- Vertex Pharmaceuticals (VRTX) Gets Positive Opinion from CHMP for KALYDECO
- Dr. Annalisa Jenkins, Executive Vice President, Head of Global Drug Development and Medical for Merck Serono, Honored by Gilda’s Club New York City
- Perrigo (PRGO) Gets FDA Approval for Generic Gynazole 1
Create E-mail Alert Related Categories
Corporate News, FDASign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
